Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-2.06M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 8.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -20.96% |
| Return on Assets (Trailing 12 Months) | -20.66% |
| Current Ratio (Most Recent Fiscal Quarter) | 86.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 86.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.32 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.53 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.48 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.93 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 7.04M |
| Free Float | 4.04M |
| Market Capitalization | $300.32M |
| Average Volume (Last 20 Days) | 0.05M |
| Beta (Past 60 Months) | -6.07 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 42.66% |
| Percentage Held By Institutions (Latest 13F Reports) | 40.52% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |